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Peroxisome proliferator-activated receptor (PPARγ), a ligand-dependent transcription factor, negatively modulates high glucose
eﬀects. We postulated that rosiglitazone (RSG), an activator of PPARγ prevents the upregulation of vascular endothelial growth
factor (VEGF) and collagen IV by mesangial cells exposed to high glucose. Primary cultured rat mesangial cells were growth-
arrested in 5.6mM (NG) or 25mM D-glucose (HG) for up to 48hours. In HG, PPARγ mRNA and protein were reduced within
3h,andenhancedROSgeneration,expressionofp22phox,VEGFandc ollagenIV ,andPK C-ζ membraneassociationwereprevented
by RSG. In NG, inhibition of PPARγ caused ROS generation and VEGF expression that were unchanged by RSG. Reduced AMP-
activated protein kinase (AMPK) phosphorylation in HG was unchanged with RSG, and VEGF expression was unaﬀected by
AMPK inhibition. Hence, PPARγ is a negative modulator of HG-induced signaling that acts through PKC-ζ but not AMPK and
regulates VEGF and collagen IV expression by mesangial cells.
Copyright © 2009 Catharine Whiteside et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The hallmark of progressive diabetic glomerulosclerosis is
the accumulation of excessive extracellular matrix protein
(ECM), mainly collagen IV, in the glomerular interstitium
[1, 2]. This results in large part from the transformation of
quiescent mesangial cells to a dediﬀerentiated myoﬁbroblast
phenotype as a result of the direct eﬀects of high glucose
and the response to autocrine and paracrine growth factors
including vascular endothelial growth factor (VEGF) and
transforming growth factor (TGF)-β [3, 4]. We and others
havedemonstratedthatearlymesangialcellresponsestohigh
glucose include the generation of reactive oxygen species
(ROS) from NADPH oxidase, a necessary signaling factor
in the stimulation of VEGF and collagen IV expression
[3, 5].
Recent studies have suggested that peroxisome pr-
oliferator-activated receptor-γ (PPARγ) synthetic agonist
thiazolidinediones, such as rosiglitazone, may prevent or
attenuate diabetic nephropathy in animal models [6, 7].
PPARγ i sam e m b e ro ft h en u c l e a rr e c e p t o rs u p e r f a m -
ily of ligand-activated transcription factors. Upon ligand
binding, PPARγ forms a heterodimer with the retinoic
X receptor. This complex then binds to PPAR response
elements (PPREs) within the promoter region of target
genes [8]. PPARγ agonists have been shown to play an
important role in regulating adipocyte diﬀerentiation, lipid
and glucose metabolism, and inﬂammation [9]. Asano et
al. [10] reported that rat mesangial cells express PPARγ
localized in the nucleus, and that troglitazone (an agonist
of PPARγ) prevents cellular dediﬀerentiation as detected by
reduced expression of α-smooth muscle actin expression.
PPARγ agonists inhibit TGF-β1 [11]a n dA n gI I[ 12]
stimulation of vascular smooth muscle cells, and mesangial
cell proliferation and ﬁbronectin synthesis in response to
VEGF [13]a n dT G F - β1 [14], respectively.2 Experimental Diabetes Research
We have demonstrated that in response to high glucose,
mesangial cells rapidly express and secrete VEGF that is
dependent on the activation of both PKC-β and PKC-ζ,a n d
the generation of reactive oxygen species (ROSs) [15]. Yang
et al. reported [16] that hyperglycemic Zucker rats develop
increased circulating VEGF and that the PPARγ agonist
pioglitazone normalized serum glucose and VEGF levels.
Onozaki et al. [13] showed that during exposure to a rapid
changeinambientglucoseconcentration,mesangialcellpro-
liferation dependent on VEGF expression was inhibited by
a thiazolidinedione. The cellular signaling mechanisms that
connect the eﬀects of high glucose to altered mesangial cell
PPARγ expression and function and consequent outcomes
relevant to progressive glomerulosclerosis are unknown.
In this study, we postulated that rosiglitazone would
reverse the eﬀects of high glucose essential for the early
responses of mesangial cells associated with myoﬁbroblast
transformation including ROS generation, VEGF and colla-
genIVexpression.ToidentifytheroleofPPARγ inmesangial
cells,wetrackedits expression andthe eﬀectsofrosiglitazone
during exposure to high glucose. The actions of rosiglitazone
on high glucose-stimulated ROS generation via NADPH
oxidase and the expression of VEGF and collagen IV were
observed. These eﬀects were conﬁrmed by similar ﬁndings
with two other PPARγ agonists, Ciglitazone and Troglita-
zone. Supporting these observations, a speciﬁc inhibitor of
PPARγ, GW9662, on mesangial cell expression of VEGF in
normal glucose and high glucose had opposite eﬀects. To
determine whether AMP-activated protein kinase (AMPK),
reported to be activated by thiazolidinediones, is involved
in this mesangial cell PPARγ pathway, the phosphorylation
of AMPK was analyzed in the presence of Compound C, a
speciﬁc antagonist of AMPK [17], with and without rosigli-
tazone. Our data support a major role for downregulation of
PPARγ during the early response of mesangial cells to high
glucose and reversal with rosiglitazone.
2.MaterialsandMethods
2.1.Materials. Dulbecco’smodiﬁedEaglemedium(DMEM)
and fetal bovine serum (FBS) were purchased from
Invitrogen Corporation (Burlington, Ont, Canada). 5-
(and-6)-chlormethyl-2 ,7 -dichlorodihydroﬂuorescein diac-
etate (CM-H2DCFDA) was obtained from Molecular Probes
Inc. (Eugene, Ore, USA). Rabbit Polyclonal antibodies
against p22phox and VEGF, and monoclonal antibodies
against PPARγ were obtained from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, Calif, USA). Monoclonal antibody
against β-actin was purchased from Sigma-Aldrich (St,
Louis, Mo, USA). Rabbit polyclonal antibody against type IV
collagen α was purchased from Rockland Immunochemicals
(Gilbertsville, Pa, USA). The rabbit polyclonal antibodies
against phospho- and total-AMPK alpha were purchased
from Cell Signaling Technology, Inc. (Danvers, Mass, USA).
The selective ATP-competitive inhibitor of AMPK, Com-
pound C, and Ciglitazone were purchased from Calbiochem
(Gibbstown, NJ, USA). Rosiglitazone and Troglitazone and
GW9662 were purchased from Cayman Chemical (Ann
Arbor, Mich, USA).
2.2. Cell Culture. Primary rat glomerular mesangial cells
were isolated from Sprague-Dawley rat kidney cortex and
cultured as previously described [18, 19]. The cells were
cultured in DMEM containing 17% FBS, then routinely
growth-arrested in 0.5% FBS for 48hours in either normal
D-glucose 5.6mM or high D-glucose 25mM, or 5.6mM D-
glucose + 24.4mM L-glucose for up to 48hours. In some
experiments, cells were incubated with 10μM rosiglitazone,
10μM Ciglitazone, 10μM Troglitazone, and/or pretreated
with 10μM GW9662 (a PPARγ antagonist). AMPK activity
wasinhibitedbypretreatmentfor48hourswith50uMCom-
pound C, a cell-permeable, selective ATP-competitive kinase
inhibitor of AMPK [17, 20, 21]. The glitazone compounds
were ﬁrst dissolved in DMSO to create a 25.2mmol/uL stock
solution stored at −20
◦C and then dissolved in DMEM to
produce a ﬁnal concentration of 10uM in the cell culture
medium.
2.3. Western Immunoblotting. Western immunoblots were
performed with primary antibodies against PPARγ,p 2 2 phox,
VEGF, AMPK, β-actin in total cell lysates, or PKC-ζ,- β1
in total cell lysates and cellular membrane fractions as we
previously described [5, 15].
2.4. Quantitative Real-Time Polymerase Chain Reaction.
Total cellular RNA was extracted from mesangial cells
using an RNeasy kit (Qiagen, Valencia, Calif, USA).
After the RNA was reverse transcribed, real-time PCR
was performed with the following primers as described
previously [15] .T h ep r i m e r sf o rV E G Fw e r e( s e n s e ) ,
5 -GA TGA GAT A GA GTA T ATCTTCAA GCCGT -3  ,a n d
(anti-sense), 5 -TCTATCTTTCTTTGGTCTGCATTCAC-3 
(Gen-Bank: NM 031836). The primers for p22phox were
(sense), 5 -TCCTCCACTTACTGCTGTCCGT-3 , and (anti-
sense), 5 -TCAATGGGAGTCCACTGCTCAC -3  (Genbank:
MIM 131550).The primers for PPARγ were (sense)
5 -CCAGAGTCTGCTGATCTGCGA-3 , and (antisense),
5 -GCCACCTCTTTGCTCTGCTC-3  (Genbank: MIM
131550). The primers for β-actin were (sense) 5 -AGG-
CCCCTCTGAACCCTAAG-3 , and (antisense), 5 -CAA-
CACAGCCTGGATGGCTAC-3  (Genbank: NM 031144).
2.5. Measurement of PPARγ Promoter Activity. To assess
PPARγ function, mesangial cells were transiently transfected
with a luciferase reporter gene containing three PPARγ
response elements and a thymidine kinase promoter [22]
obtained from Addgene (Cambridge, Mass, USA). Cells were
platedin24wellplatesandtransfectedwithFugene6(Roche,
Indianapolis, Ind, USA) according to the manufacturer’s
instructions. For measurement of luciferase activity, the
transfected mesangial cells were growth-arrested in 0.5%
FBS in 5.6mM or 25mM D-glucose for up to 48hours.
In some experiments, 10uM rosiglitazone or/and 10μM
GW9662 was added to the medium for 48hours. The
mesangial cells were then lysed on ice in a buﬀer containing
glycylglycine 25mM, pH 8, MgSO4 15mM, EGTA 4mM,
1% Triton X-100. Luciferase activity was detected in 50uL
of cell extract plus 100uL of reaction buﬀer (glycylglycine
25mM, pH 8, KH2PO4 15mM, EGTA 4mM, ATP 2mM,Experimental Diabetes Research 3
MgSO4 15mM, and CoA 0.1mM) over 20seconds in a plate
reading luminometer. The results were normalized to total
cell protein.
2.6. Confocal Imaging. To analyze collagen IV protein con-
tent, cells were cultured on glass coverslips and incubated
with polyclonal antibody against collagen IV. The primary
antibodies were detected using FITC-conjugated goat anti-
rabbitIgG(JacksonImmunoresearchLaboratories,Inc;West
Grove, Pa, USA). Immunoﬂuorescence was observed by
confocal imaging and ﬂuorescence intensity per cell was
analyzed as previously described [5, 15].
To analyze hydrogen peroxide content, mesangial cells
were cultured on glass coverslips and incubated in the
dark with 1μMo fC M - H 2DCFDA for 25minutes at 37
◦C.
Intracellular ROS production was detected by confocal
laser scanning microscopy. Fluorescence intensity per cell
was analyzed by Scion Image software (Scion Corporation,
Frederick, Md, USA) as previously described [5, 15].
2.7. Statistical Analyses. All results are expressed as mean ±
SEM. Statistical analyses were performed using Instat 2.01
(Graph Pad, Sacramento, Calif, USA). Unpaired Student
t tests were used to compare the means of two groups.
One-way analysis of variance (ANOVA) was performed to
compare the means of three groups or more, then the
Tukey-Kramer multiple comparison test was applied for post
test analysis. P< . 05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Eﬀects of High Glucose and Rosiglitazone on PPARγ
Expression. Mesangial cell expression of PPARγ in high glu-
cose was analyzed by incubating cells with 5.6mM (normal
glucose) or 25mM (high glucose) D-glucose, or 5.6mM
D-glucose + 24.4mM L-glucose for up to 48hours, with
and without rosiglitazone. L-Glucose exposure for 48hours
had no eﬀect on PPARγ mRNA expression. Figure 1(a)
shows that in high glucose, PPARγ protein expression
w a sr e d u c e db y3 h o u r sa n ds u s t a i n e du pt o4 8 h o u r sa s
demonstrated by Western immunoblot. PPARγ mRNA levels
were signiﬁcantly reduced by 24hours continuing up to
48hours Figure 1(b). We also demonstrated that neither
rosiglitazone nor GW6992 (an antagonist of PPARγ), altered
PPARγ p r o t e i nl e v e l si nh i g hg l u c o s e[ 17, 23] Figure 1(c).
To investigate whether PPARγ activation of transcription
is reduced in high glucose and if rosiglitazone alters this
response, mesangial cells were transiently transfected with
aP P A R γ-luciferase reporter gene as described by others
[24, 25]. Decreased luciferase activity was found at 1 to
48hoursofexposuretohighglucoseasshowninFigure 1(d).
ThesedatasuggestthatdownregulationofPPARγ expression
in high glucose reduces the functional eﬀect of PPARγ
on promoter activity. To determine whether rosiglitazone
modulates PPARγ stimulation of promoter activity, mesan-
gial cells were pre-incubated with 1 to 20uM rosiglitazone
and promoter activity was measured. A maximum eﬀect
on luciferase activity was observed in normal glucose in
the cells incubated with 5uM rosiglitazone Figure 1(e),a n d
in high glucose, 10uM rosiglitazone stimulated luciferase
to a similar maximum Figure 1(f). We then found that
inhibition of PPARγ receptor activity with GW6992 pre-
vented the rosiglitazone-stimulated PPAR-γ responsive pro-
moter activity both in normal glucose and high glucose
Figure 1(f).
3.2. ROS Generation Regulated by PPARγ. In high glucose,
ROS generation appeared within 1 to 3hours in DCF-loaded
mesangial cells (Figure 2), as previously reported [5, 15].
We observed that 1hour pretreatment with rosiglitazone
abolished ROS generation during 3 to 48hours of exposure
to high glucose Figure 2(a).T h i se ﬀect of rosiglitazone
was blocked by preincubation with GW9662 Figure 2(b).
GW9662 alone caused generation of ROS in normal
glucose.
We have reported that the NADPH oxidase subunit,
p22phox is upregulated in high glucose in mesangial cells
[15]. To determine whether PPARγ activation modiﬁes high
glucose-induced p22phox expression, mesangial cells were
exposed to 5.6mM or 25mM D-glucose for up to 48hours.
First, the cells were preincubated with 10μM rosiglitazone
alone. As displayed in Figure 3(a), p22phox protein levels
in high glucose were increased as expected at 24hours and
48hours. Rosiglitazone not only prevented the eﬀect of high
glucose on p22phox protein but also reduced the ambient
level of this protein in normal glucose. Further, cells were
tested with three diﬀerent PPARγ activators that all blocked
high glucose-induced p22phox protein expression as shown in
Figure 3(b).
3.3. Rosiglitazone Prevents High Glucose-Induced VEGF and
Collagen IV Expression in Mesangial Cells. To test the eﬀect
of PPARγ activation and inhibition on VEGF expres-
sion, mesangial cells were growth-arrested and exposed
to 5.6mM or 25mM D-glucose for up to 48hours, with
or without rosiglitazone or GW9662. The increase in
VEGF mRNA levels was prevented by pretreatment with
rosiglitazone Figure 4(a). Both Ciglitazone and Troglitazone
also blocked high glucose-stimulated VEGF expression at
48hours as detected by Western immunoblot Figure 4(b).
Then, enhanced VEGF protein expression in high glucose
was inhibited by pretreatment with 10uM rosiglitazone at
both 24hours and 48hours Figure 4(c) as detected by West-
ern immunoblot. The inhibition of PPARγ with GW9662
alone in normal glucose caused a signiﬁcant increase in
VEGF expression. Furthermore, this inhibitor reversed the
eﬀect of rosiglitazone on VEGF expression in mesangial cells
in high glucose Figure 4(d).
To determine the eﬀect of rosiglitazone on collagen
IV expression, we ﬁrst analyzed the eﬀect of this PPARγ
activator on high glucose-induced mRNA expression. A
signiﬁcant increase in collagen IV mRNA was observed after
48hours, but not 3hours, in high glucose and this response
was inhibited by rosiglitazone Figure 5(a).I n t r a c e l l u l a rc o l -
lagen IV protein expression was assessed by immunoﬂuo-
rescence imaging. The increase in collagen IV protein at 34 Experimental Diabetes Research
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Figure 1: Eﬀect of high glucose on PPARγexpression. Rat glomerular mesangial cells were cultured in 5.6mM (NG) or 25mM D-glucose
( H G ) ,o r5 . 6m MD - g l u c o s e+2 4 . 4m ML - g l u c o s e( L G )f o ru pt o4 8h o u r s .( a )P P A R γ was detected by immunobloting in total cell lysates,
using β-actin as the loading controls. The graphs represent PPARγ protein levels relative to NG. (b) PPARγ mRNA levels were determined
by real-time RT-PCR. (n = 4–6, ∗P<. 05 versus NG; ∗∗P<. 01 versus NG). (c) Preincubated with 10μM rosiglitazone (RSG) or/and 10μM
GW9662, the protein expression of PPARγ was not aﬀected by RSG or GW6992 in HG (n = 5,∗ P< . 05 versus NG). Mesangial cells were
transiently transfected with a luciferase reporter gene containing three PPAR response elements and then cultured in the above conditions.
(d) Luciferase reporter activity was reduced in HG (n = 5,∗ P<. 05 versus NG, ∗∗P< . 01 versus NG). (e) In NG, PPARγ promoter activity
increased in dose response to RSG (n = 4, ∗P<. 01 versus NG). (f) GW6992 blocked the eﬀect of RSG (n = 4–6, ∗P<. 01 versus NG alone,
∗∗P<. 05 versus NG or HG alone, ∗∗∗P<. 05 versus NG or HG with RSG).
and 24hours was prevented by rosiglitazone pretreatment
Figure 5(b).
3.4. Eﬀect of Rosiglitazone on PKC-β1 and -ζ Membrane
Translocation. Since our previous studies indicated a cause-
and-eﬀect relationship among the activation of PKC-β1 and
PKC-ζ, ROS generation and both VEGF and collagen IV
expression [5, 15], we wished to test whether rosiglitazone
could aﬀect these two key PKC isozymes that are relevant to
the pathogenesis of diabetic glomerulophathy. As illustrated
in Figure 6, in the presence of rosiglitazone, a reduction
in membrane-association of PKC-ζ,b u tn o tP K C - β1,w a s
observed in both normal and high glucose. Total recoveries
of both PKC isozymes in total cell lysate were unchanged in
high glucose or in the presence of rosiglitazone.
3.5. Rosiglitazone and the AMPK Pathway. It has been
reported that rosiglitazone reduces ROS production by
NADPH oxidase independent of PPARγ activity and that
this eﬀect may involve the AMPK pathway [17]. Thus, we
determined whether inhibition of AMPK with Compound C
would reverse the inhibition of ROS generation in responseExperimental Diabetes Research 5
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Figure 2:Eﬀectofrosiglitazoneonreactiveoxygenspeciesgeneration.Mesangialcellswereexposedto5.6mM(NG)or25mM(HG)D-glucose
f o ru pt o4 8h o u r s ,a n dp r e t r e a t e dw i t h1 0μM rosiglitazone (RSG) or GW9662 for 1hour. Reactive oxygen species (ROS) were detected in
DCF-loaded cells by confocal ﬂuorescence imaging in 3 or 4 separate experiments for each condition. (a) ROS generation was inhibited
by RSG (n = 147–218 cells, ∗P< . 001 versus NG, ∗∗P<. 001 versus HG 3hours, HG 24hours, or HG 48hours). (b) ROS generation in
NG was stimulated with GW9662 (n = 130–189 cells, ∗P< . 001 versus NG, ∗∗P<. 001 versus HG 48hours without RSG or GW9662).
Magniﬁcation bar = 25μM.
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Figure 3: NADPH oxidase subunit p22phoxexpression. Mesangial
c e l l sw e r ee x p o s e dt o5 . 6 m M( N G )o r2 5 m M( H G )D - g l u c o s e
for 24hours or 48hours, or pretreated with 10μM rosiglitazone
(RSG), or 10μM ciglitazone or 10μM troglitazone) and p22phox
was detected by immunoblotting. Pretreatment with three diﬀerent
PPARγ agonists blocked HG-induced p22phox expression (n = 5,
∗P<. 05 versus NG, ∗∗P< . 05 versus HG 24hours or HG
48hours).
to HG observed during rosiglitazone treatment. Mesangial
cells were growth-arrested and exposed to 5.6mM or
25mM D-glucose for up to 3hours or 48hours, with or
without 1hour pretreatment with 10μM rosiglitazone or
50μM Compound C, or both. In Figure 7, the eﬀect of
rosiglitazone on high glucose-induced ROS generation
was reversed by coincubation with Compound C. Of note
was that Compound C alone caused ROS generation in
normal glucose at 48hours. The enhanced generation of
ROS by mesangial cells observed in high glucose at 3 and
48hours was not aﬀe c t e db yC o m p o u n dC .H o w e v e r ,i nt h e
presence of Compound C, the eﬀect of rosiglitazone on ROS
generation in high glucose was reversed in keeping with a
possible AMPK-independent eﬀect of Compound C on ROS
generation.
The phosphorylation of AMPK in normal and high
glucose at 3hours was inhibited with Compound C as
illustrated in Figure 8. In view of the generation of ROS
during exposure to Compound C, these experiments were
limited to 3hours. VEGF protein expression in high glucose
was also analyzed in the same protein samples. Rosiglitazone
had no eﬀect on AMPK phosphorylation in either normal
or high glucose. While Compound C, as expected, inhibited
AMPK phosphorylation in both normal and high glucose,
it had no eﬀect on VEGF expression in normal or high
glucose. Furthermore, the inhibitory eﬀect of rosiglitazone6 Experimental Diabetes Research
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Figure 4: Rosiglitazone prevented high glucose-induced VEGF expression. Mesangial cells were placed in 5.6mM (NG) or 25mM (HG) D-
glucose for the indicated times or pretreated with PPARγ agonists (10μM Ciglitazone, or 10μM Troglitazone, or 10μMR G S )f o r1h o u r .( a )
VEGF mRNA levels were detected by real-time PCR (n = 4, ∗P<. 05 versus NG, ∗∗P<. 01 versus HG). (b) Pretreatment with three diﬀerent
PPARγ agonists similarly blocked HG-induced VEGF expression at 48hours as detected by immunobloting (n = 4, ∗P<. 01 versus
NG, ∗∗P<. 01 versus HG). (c) Rosiglitazone alone prevented HG-induced VEGF expression at both 24hours and 48hours as detected by
immunoblotting in total cell lysates using β-actin as the loading control. The graphs represent VEGF protein levels relative to NG (n = 5,
∗P<. 01 versus NG, ∗∗P<. 01 versus HG). (d) GW9662 reverses the eﬀect of RSG, (n = 5, ∗P< . 01 versus NG without RSG or GW9662 ,
∗∗P<. 001 versus NG without RSG or GW9662).Experimental Diabetes Research 7
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Figure 5: Rosiglitazone prevented high glucose-induced collagen IV
expression. Mesangial cells were exposed to 5.6mM (NG) or 25mM
(HG) for up to 48hours pretreated with 10μM rosiglitazone (RSG)
for 1hour. (a) The expression of collagen IV (α1) mRNA was
detected by real-time RT-PCR (n = 4, ∗P<. 05 versus NG).
(b) Representative confocal microscopic images show collagen IV
staining without (C) or with RSG. Immunoﬂuorescence intensity
per cell was analyzed (n = 76–136 cells, ∗∗P<. 01 versus NG).
Magniﬁcation bar = 25μM.
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Figure 6: PKC-β1 and PKC-ζ response to high glucose and rosiglita-
zone.Mesangialcellswereexposedto5.6mM(NG)or25mM(HG)
f o r3h o u r so r4 8h o u r sp r e t r e a t e dw i t h1 0μM rosiglitazone (RSG)
for 1hour. PKC-β1 and PKC-ζ were detected in total cell lysates
or membrane fractions with immunoblotting. (a) Representative
immunoblotsofPKC-β1 andPKC-ζ.(b)Quantitativeanalysisofthe
immunoblots (n = 5, ∗P<. 05 versus NG without RSG, ∗∗P<. 01
versus HG without RSG).
on enhanced VEGF expression at 3hours in high glucose was
not signiﬁcantly aﬀected by Compound C Figure 8(b).
4. Discussion
In this study, we identiﬁed that within the ﬁrst 6hours of
exposure to high glucose, mesangial cell PPARγ is downreg-
ulated and that rosiglitazone prevents the eﬀects of high glu-
cose on NADPH oxidase-dependent ROS generation, VEGF
and collagen IV expression. The analysis of PPARγ protein
levels indicated a reduction as early as 3hours following high
glucose exposure, although signiﬁcant reduction in PPARγ
mRNA levels was not detected until 6hours, suggesting
that high glucose may diﬀerentially alter translation and
transcription. Diﬀerential regulation of PPARγ protein and
mRNA levels in high glucose could also be due to enhanced
protein degradation following activation as demonstrated
by Hauser et al. [26]. We demonstrated the dose response
of the PPARγ-stimulated promoter activity in response
to increasing concentrations of rosiglitazone. Two other
PPARγ agonists, Ciglitazone and Troglitazone prevented
high glucose-induced p22phox and VEGF expression. Our
data support the conclusion that rosiglitazone prevents the8 Experimental Diabetes Research
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Figure 7: Compound C reversed rosiglitazone prevented high glucose-
induced reactive oxygen species generation. Mesangial cells were
exposed to 5.6mM (NG) or 25mM (HG) for 3hours or 48hours,
and then pretreated with 10μM rosiglitazone (RSG) or 50μM
compound C (CPC), or combination of both, for 1hour. Reactive
oxygenspecies(ROS)generationwasmeasuredinDCF-loadedcells
using confocal ﬂuorescence imaging. RSG prevented high glucose
stimulated ROS production that was abolished by coincubation
with CPC (n = 145–204 cells, ∗P<. 05 versus NG in the absence
of RSG and/or CPC, ∗∗P<. 01 versus HG in the absence of RSG
and/or CPC). Magniﬁcation bar = 25μM.
eﬀects of high glucose on mesangial cell signaling and gene
expression through PPARγ.
We also found that rosiglitazone prevented high glucose-
induced upregulation of NADPH oxidase subunit, p22phox
expression, correlating with the eﬀect of rosiglitazone in
attenuating ROS generation in response to high glucose.
Further, an antagonist of the PPARγ receptor, GW9662,
caused ROS generation in normal glucose and prevented
the eﬀects of rosiglitazone. These data also support the
conclusion that the eﬀects of rosiglitazone in mesangial cells
are likely mediated through PPARγ. Our ﬁndings agree with
those recently reported by Henderson et al. [27]a n dT y a g i
et al. [28] who found that a PPARγ agonist (Ciglitazone)
prevented the ROS generation that was associated with
an upregulation of the NADPH oxidase subunit (Nox4)
in response to pressure overload and homocysteine in
myocardium and in endothelial cells, respectively. The com-
bination of PPARα and γ activators also inhibits angiotensin
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Figure 8: Eﬀects of Compound C on AMP kinase activity and
VEGF in high glucose. Mesangial cells were exposed to 5.6mM
(NG) or 25mM (HG) for 3hours, and then pretreated with
10μMr o s i g l i t a z o n e( R S G )o r5 0 μM compound C (CPC), or
combination of both, for 1hour. Total AMP kinase (T-AMPK),
phosphorylated AMPK (P-AMPK) and VEGF were detected in the
same total cell lysate samples with immunoblotting. CPC inhibited
phosphorylation of AMPK in NG and HG, but had no eﬀect on
the inhibition of VEGF expression in HG. RSG had no eﬀect on P-
AMPK. (n = 3, ∗ P<. 05 versus VEGF in NG, ∗∗P<. 05 versus
VEGF in HG 3hours without RSG or CPC, ∗∗∗P<. 05 versus P-
AMPK in HG 3hours without RSG or CPC).
II-induced ROS production by NADPH oxidase in hyper-
tensive rats [29]. Hwang et al. [30] recently reported that
rosiglitazone reduces vascular oxidative stress and NADPH
oxidase subunit expression in diabetic mice. We have shown
that sustained production of ROS in mesangial cells in
high glucose may be due to the upregulation of NADPH
oxidase subunits, p47phox and p22phox via a PKC-dependent
mechanism[5,31].Thepresentstudyextendsourﬁndingsto
includearoleforPPARγ inthenegativeregulationofp22phox
expression in mesangial cells in the normal state as well as
reversal of the increase induced by high glucose.
Recently, we published that in high glucose the upregu-
lation of VEGF expression by mesangial cells is dependent
on ROS generation by NADPH oxidase [15]. Evidence is
increasing for an important functional relationship between
PPAR and VEGF. Xin et al. [32] reported that the activation
ofPPARγ withCiglitazoneinhumanumbilicalveinendothe-
lial cells reduced VEGF receptor 1 (Flt1) and 2 (Flk/KDR)
expression. Further, Meissner et al. [33] demonstrated
that PPARα activators inhibit VEGF receptor 2 expressionExperimental Diabetes Research 9
via inhibition of Sp1-dependent DNA binding and trans-
activation. In endothelial cells, PPARγ activators inhib-
ited VEGF-induced AKT phosphorylation and consequent
endothelial cell migration [34]. Our present data are consis-
tent with these reports and show that rosiglitazone abolished
high glucose-stimulated VEGF expression in mesangial cells.
Our ﬁndings also illustrate that rosiglitazone prevented
collagen IV expression by mesangial cells in high glucose.
These results are in keeping with a number of studies
relating PPAR activation to the prevention of extracellular
matrix production relevant to kidney disease. Accelerated
nephropathy is observed in diabetic PPARα-knockout mice
due to collagen IV deposition [35]. The PPARα agonist
fenoﬁbrate prevents diabetic nephropathy in db/db mice
[36]. In human kidney ﬁbroblasts, the PPARγ agonist,
pioglitazone, reduces extracellular matrix production [37].
In mesangial cells, the PPARγ agonist thiazolidinediones
inhibit TGF-β1-induced ﬁbronectin expression and amelio-
rate diabetic nephropathy [38, 39]. In renal tubular cells,
pioglitazone activation of PPARγ exerts antiﬁbrotic eﬀects
in the setting of high glucose [40]. These ﬁndings do not
excludethepossibilitythatPPARγ activationinvivomayalso
preventtheaccumulationofcollagenIVthroughsuppression
of plasminogen activator inhibitor-1 [41].
To identify the mechanism(s) whereby PPARγ regulates
mesangial cell signaling and gene expression, we examined
the eﬀect of rosiglitazone on PKC-β1 and -ζ membrane-
association patterns and on AMPK phosphorylation. The
membrane-association of PKC-ζ was inhibited by rosigli-
tazone, whereas PKC-β1 was unaﬀected. We previously
demonstrated the cause-and-eﬀect relationship between the
activation of mesangial cell PKC-ζ in high glucose and
subsequent generation of ROS, VEGF, and collagen IV
expression in response to high glucose [5, 15]. Therefore, the
observation that a PPARγ activator appears to inhibit PKC-
ζ membrane association links PPARγ to this speciﬁc PKC
isozyme pathway. By contrast, rosiglitazone had no eﬀect on
AMPKphosphorylation,suggestingthatPPARγ inmesangial
cellsmaynotsignalthroughthispathway.Theseresultsdiﬀer
from a recent report in which rosiglitazone was observed
to reduce glucose-induced oxidative stress mediated by
NADPH oxidase via an AMPK-dependent mechanism in
endothelial cells [17, 42]. In human neutrophils, AMPK
activation inhibits ROS generation by NADPH oxidase [23].
We observed that in high glucose, mesangial cell AMPK
phosphorylation was reduced. Taken together with the
observation that inhibition of AMPK with Compound C was
associated with ROS generation, it is possible that AMPK
regulates ROS generation in mesangial cells, but separately
from the action of PPARγ. It appears that the signaling
response of AMPK in high glucose may vary depending on
the cell phenotype.
The precise mechanism whereby PPARγ inhibits high
glucose-stimulated VEGF, ROS formation, collagen IV
expression, and PKC-ζ is not known at present. A well-
documented eﬀect of PPARγ is to inhibit TGF-β expression
and/or TGF-β signaling giving rise to an antiﬁbrotic eﬀect,
which can be demonstrated in vivo in models of lung
ﬁbrosis for example [38, 43]. Given that we have recently
found that all of the above eﬀects of high glucose depend
on TGF-β [44], inhibition of TGF-β and its downstream
signaling could account for the inhibitory eﬀects of PPARγ
observed in the present study. Intriguingly, PPARγ has been
variably shown to prevent DNA binding, and in some cases
to interact physically with diﬀerent transcription factors,
such as AP-1 [45], Sp1 [33, 46], nuclear factor-1 (NF-1)
[47], NF-κB[ 48]. Therefore, one could hypothesize that
suppression of AP-1, Sp1, NF-1, or NF-κB DNA binding
could be suﬃcient to account for the eﬀects of PPARγ by
reducing TGF-β expression, interfering with the expression
of proteins involved in TGF-β signaling, and perhaps by
directly aﬀecting the expression of some of the above
proteins, such as collagen IV, p22phox, and VEGF.
In summary, mesangial cells demonstrate rapid down-
regulation of PPARγ via both transcriptional and nontran-
scriptional regulation in response to high glucose. Treatment
with rosiglitazone, linked to the PKC-ζ pathway, attenuates
high glucose-induced ROS generation and prevents VEGF
and collagen IV expression through its action on PPARγ.
This study suggests that preventing the actions of high
glucose on mesangial cell PPARγ may be relevant in the
treatment and prevention of diabetic glomerulopathy.
Acknowledgments
This work was supported by the Canadian Diabetes Associa-
tion (C. Whiteside) and in part by grants from the Canadian
Institutes of Health Research (CIHR) to I. G. Fantus (MOP
83025 and MOP 49409). L. Xia was a Post-doctoral fellow
supported by the Canadian Diabetes Association and CIHR
(MOP 49409).
References
[1] S. G. Adler, S. Feld, L. Striker, et al., “Glomerular type
IV collagen in patients with diabetic nephropathy with and
without additional glomerular disease,” Kidney International,
vol. 57, no. 5, pp. 2084–2092, 2000.
[2] R. M. Mason and N. A. Wahab, “Extracellular matrix
metabolism in diabetic nephropathy,” J o u r n a lo ft h eA m e r i c a n
Society of Nephrology, vol. 14, no. 5, pp. 1358–1373, 2003.
[3] M. Haneda, D. Koya, M. Isono, and R. Kikkawa, “Overview of
glucose signaling in mesangial cells in diabetic nephropathy,”
JournaloftheAmericanSocietyofNephrology,vol.14,no.5,pp.
1374–1382, 2003.
[4] Y. Mao, T. Ootaka, T. Saito, H. Sato, T. Sato, and S. Ito, “The
involvement of advanced glycation endproducts (AGEs) in
renal injury of diabetic glomerulosclerosis: association with
phenotypic change in renal cells and inﬁltration of immune
cells,” Clinical and Experimental Nephrology,v o l .7 ,n o .3 ,p p .
201–209, 2003.
[5] L. Xia, H. Wang, S. Munk, et al., “Reactive oxygen species,
PKC-β1,a n dP K C - ζ mediate high-glucose-induced vascular
endothelial growth factor expression in mesangial cells,”
American Journal of Physiology, vol. 293, no. 5, pp. E1280–
E1288, 2007.
[6] A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen,
M. E. Cooper, and M. C. Thomas, “PPAR-α and -γ agonists
attenuate diabetic kidney disease in the apolipoprotein E10 Experimental Diabetes Research
knockout mouse,” Nephrology Dialysis Transplantation, vol.
21, no. 9, pp. 2399–2405, 2006.
[7] U. Panchapakesan, X. M. Chen, and C. A. Pollock,
“Druginsight:thiazolidinedionesanddiabeticnephropathy—
relevance to renoprotection,” Nature Clinical Practice Nephrol-
ogy, vol. 1, no. 1, pp. 33–43, 2005.
[8] J. Berger and D. E. Moller, “The mechanisms of action of
PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435,
2002.
[ 9 ]Y .G u a n ,Y .Z h a n g ,a n dM .D .B r e y e r ,“ T h er o l eo fP P A R si n
the transcriptional control of cellular processes,” Drug News
and Perspectives, vol. 15, no. 3, pp. 147–154, 2002.
[10] T. Asano, M. Wakisaka, M. Yoshinari, et al., “Peroxisome
proliferator-activated receptor γ1( P P A R γ1) expresses in rat
mesangial cells and PPARγ agonists modulate its diﬀerentia-
tion,” Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148–
154, 2000.
[11] M. Fu, J. Zhang, Y. Lin, et al., “Early stimulation and late
inhibition of peroxisome proliferator-activated receptor γ
(PPARγ) gene expression by transformino growth factor β
in human aortic smooth muscle cells: role of early growth-
response factor-1 (Egr-1), activator protein 1 (AP1) and
Smads,” Biochemical Journal, vol. 370, no. 3, pp. 1019–1025,
2003.
[12] S. Wakino, K. Hayashi, T. Kanda, et al., “Peroxisome
proliferator-activated receptor gamma ligands inhibit
Rho/Rho kinase pathway by inducing protein tyrosine
phosphatase SHP-2,” Circulation Research, vol. 95, no. 5, pp.
e45–e55, 2004.
[13] A. Onozaki, S. Midorikawa, H. Sanada, et al., “Rapid change
ofglucoseconcentrationpromotesmesangialcellproliferation
viaVEGF:inhibitoryeﬀectsofthiazolidinedione,” Biochemical
and Biophysical Research Communications, vol. 317, no. 1, pp.
24–29, 2004.
[14] A. Maeda, S. Horikoshi, T. Gohda, T. Tsuge, K. Maeda,
and Y. Tomino, “Pioglitazone attenuates TGF-β1-induction
of ﬁbronectin synthesis and its splicing variant in human
mesangial cells via activation of peroxisome proliferator-
activatedreceptor(PPAR)γ,” CellBiologyInternational,vol.29,
no. 6, pp. 422–428, 2005.
[ 1 5 ] L .X i a ,H .W a n g ,H .J .G o l d b e r g ,S .M u n k ,I .G .F a n t u s ,a n dC .
I. Whiteside, “Mesangial cell NADPH oxidase upregulation in
high glucose is protein kinase C dependent and required for
collagen IV expression,” American Journal of Physiology, vol.
290, no. 2, pp. F345–F356, 2006.
[16] B.Yang,P.Lin,K.M.Carrick,etal.,“PPARγ agonistsdiminish
serum VEGF elevation in diet-induced insulin resistant SD
rats and ZDF rats,” Biochemical and Biophysical Research
Communications, vol. 334, no. 1, pp. 176–182, 2005.
[17] G. Ceolotto, A. Gallo, I. Papparella, et al., “Rosiglita-
zone reduces glucose-induced oxidative stress mediated by
NAD(P)H oxidase via AMPK-dependent mechanism,” Arte-
riosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12,
pp. 2627–2633, 2007.
[18] J. A. Dlugosz, S. Munk, J. Kapor-Drezgic, et al., “Stretch-
induced mesangial cell ERK1/ERK2 activation is enhanced
in high glucose by decreased dephosphorylation,” American
Journal of Physiology, vol. 279, no. 4, pp. F688–F697, 2000.
[19] J. Kapor-Drezgic, X. Zhou, T. Babazono, J. A. Dlugosz, T.
Hohman, and C. I. Whiteside, “Eﬀect of high glucose on
mesangial cell protein kinase and C-δ and -ε is polyol
pathway-dependent,” Journal of the American Society of
Nephrology, vol. 10, no. 6, pp. 1193–1203, 1999.
[20] J. Pandhare, S. K. Cooper, and J. M. Phang, “Proline oxidase,
a proapoptotic gene, is induced by troglitazone: evidence for
both peroxisome proliferator-activated receptor γ-dependent
and -independent mechanisms,” The Journal of Biological
Chemistry, vol. 281, no. 4, pp. 2044–2052, 2006.
[ 2 1 ]J . - M .Y e ,N .D z a m k o ,A .J .H o y ,M .A .I g l e s i a s ,B .K e m p ,a n d
E. Kraegen, “Rosiglitazone treatment enhances acute AMP-
activated protein kinase-mediated muscle and adipose tissue
glucose uptake in high-fat-fed rats,” Diabetes, vol. 55, no. 10,
pp. 2797–2804, 2006.
[ 2 2 ]B .M .F o r m a n ,P .T o n t o n o z ,J .C h e n ,R .P .B r u n ,B .M .
Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin
J2 is a ligand for the adipocyte determination factor PPARγ,”
Cell, vol. 83, no. 5, pp. 803–812, 1995.
[ 2 3 ] G .A l b a ,R .E lB e k a y ,M .´ Alvarez-Maqueda, et al., “Stimulators
of AMP-activated protein kinase inhibit the respiratory burst
in human neutrophils,” FEBS Letters, vol. 573, no. 1–3, pp.
219–225, 2004.
[24] A. Aiello, G. Pandini, F. Frasca, et al., “Peroxisomal
proliferator-activated receptor-γ agonists induce partial rever-
sion of epithelial-mesenchymal transition in anaplastic thy-
roid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–
4475, 2006.
[ 2 5 ]F .T u r t u r r o ,R .O l i v e rI I I ,E .F r i d a y ,I .N i s s i m ,a n dT .
Welbourne, “Troglitazone and pioglitazone interactions via
PPAR-γ-independent and -dependent pathways in regulating
physiological responses in renal tubule-derived cell lines,”
American Journal of Physiology, vol. 292, no. 3, pp. C1137–
C1146, 2007.
[ 2 6 ]S .H a u s e r ,G .A d e l m a n t ,P .S a r r a f ,H .M .W r i g h t ,E .M u e l l e r ,
and B. M. Spiegelman, “Degradation of the peroxisome
proliferator-activated receptor γ is linked to ligand-dependent
activation,” The Journal of Biological Chemistry, vol. 275, no.
24, pp. 18527–18533, 2000.
[27] B. C. Henderson, U. Sen, C. Reynolds, et al., “Reversal of sys-
temic hypertension-associated cardiac remodeling in chronic
pressure overload myocardium by ciglitazone,” International
Journal of Biological Sciences, vol. 3, no. 6, pp. 385–392, 2007.
[28] N. Tyagi, K. S. Moshal, U. Sen, D. Lominadze, A.
V. Ovechkin, and S. C. Tyagi, “Ciglitazone ameliorates
homocysteine-mediated mitochondrial translocation and
matrix metalloproteinase-9 activation in endothelial cells by
inducing peroxisome proliferator activated receptor-γ activ-
ity,” Cellular and Molecular Biology, vol. 52, no. 5, pp. 21–27,
2006.
[29] C. De Ciuceis, F. Amiri, M. Iglarz, J. S. Cohn, R. M. Touyz,
a n dE .L .S c h i ﬀrin, “Synergistic vascular protective eﬀects
of combined low doses of PPARα and PPARγ activators in
angiotensin II-induced hypertension in rats,” British Journal
of Pharmacology, vol. 151, no. 1, pp. 45–53, 2007.
[30] J. Hwang, D. J. Kleinhenz, H. L. Rupnow, et al., “The
PPARγ ligand, rosiglitazone, reduces vascular oxidative stress
and NADPH oxidase expression in diabetic mice,” Vascular
Pharmacology, vol. 46, no. 6, pp. 456–462, 2007.
[31] A. Fontayne, P. M. Dang, M. A. Gougerot-Pocidalo, and J. El-
Benna, “Phosphorylation of p47phox sites by PKC α, βII, δ,
and ζ:e ﬀect on binding to p22phox and on NADPH oxidase
activation,” Biochemistry, vol. 41, no. 24, pp. 7743–7750, 2002.
[ 3 2 ] X .X i n ,S .Y a n g ,J .K o w a l s k i ,a n dM .E .G e r r i t s e n ,“ P e r o x i s o m e
proliferator-activated receptor gamma ligands are potent
inhibitors of angiogenesis in vitro and in vivo,” The Journal
of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.Experimental Diabetes Research 11
[33] M. Meissner, M. Stein, C. Urbich, et al., “PPARα activa-
tors inhibit vascular endothelial growth factor receptor-2
expression by repressing Sp1-dependent DNA binding and
transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–
332, 2004.
[34] S. Goetze, F. Eilers, A. Bungenstock, et al., “PPAR activators
inhibit endothelial cell migration by targeting Akt,” Biochem-
ical and Biophysical Research Communications, vol. 293, no. 5,
pp. 1431–1437, 2002.
[ 3 5 ]C .W .P a r k ,H .W .K i m ,S .H .K o ,e ta l . ,“ A c c e l e r a t e dd i a b e t i c
nephropathy in mice lacking the peroxisome proliferator-
activated receptor α,” Diabetes, vol. 55, no. 4, pp. 885–893,
2006.
[36] C. W. Park, Y. Zhang, X. Zhang, et al., “PPARα agonist
fenoﬁbrate improves diabetic nephropathy in db/db mic,”
Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006.
[37] S. Zaﬁriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik,
and C. A. Pollock, “Pioglitazone inhibits cell growth and
reduces matrix production in human kidney ﬁbroblasts,”
J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y , vol. 16, no. 3,
pp. 638–645, 2005.
[38] B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M.
Haneda,“Peroxisomeproliferator-activatedreceptor-γ ligands
inhibit TGF-β1-induced ﬁbronectin expression in glomerular
mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–208, 2004.
[39] T. Okada, J. Wada, K. Hida, et al., “Thiazolidinediones
ameliorate diabetic nephropathy via cell cycle-dependent
mechanisms,” Diabetes, vol. 55, no. 6, pp. 1666–1677, 2006.
[40] U. Panchapakesan, S. Sumual, C. A. Pollock, and X. Chen,
“PPARγ agonists exert antiﬁbrotic eﬀects in renal tubular cells
exposed to high glucose,” American Journal of Physiology, vol.
289, no. 5, pp. F1153–F1158, 2005.
[41] X. Yu, C. Li, X. Li, and L. Cai, “Rosiglitazone prevents
advanced glycation end products-induced renal toxicity likely
through suppression of plasminogen activator inhibitor-1,”
Toxicological Sciences, vol. 96, no. 2, pp. 346–356, 2007.
[42] M.-H. Zou and Y. Wu, “AMP-activated protein kinase activa-
tion as a strategy for protecting vascular endothelial function,”
Clinical and Experimental Pharmacology and Physiology, vol.
35, no. 5-6, pp. 535–545, 2008.
[43] J. E. Milam, V. G. Keshamouni, S. H. Phan, et al., “PPAR-γ
agonists inhibit proﬁbrotic phenotypes in human lung ﬁbrob-
lasts and bleomycin-induced pulmonary ﬁbrosis,” American
Journal of Physiology, vol. 294, no. 5, pp. L891–L901, 2008.
[44] L. Xia, H. Wang, S. Munk, et al., “High glucose activates PKC-
ζ and NADPH oxidase through autocrine TGF-β1 signaling in
mesangial cells,” American Journal of Physiology, vol. 295, no.
6, pp. F1705–F1714, 2008.
[45] S. Hazra, S. Xiong, J. Wang, et al., “Peroxisome proliferator-
activated receptor γ induces a phenotypic switch from
activated to quiescent hepatic stellate cells,” The Journal of
Biological Chemistry, vol. 279, no. 12, pp. 11392–11401, 2004.
[46] A. Sugawara, A. Uruno, M. Kudo, et al., “Transcription
suppression of thromboxane receptor gene by peroxisome
proliferator-activated receptor-γ via an interaction with Sp1
in vascular smooth muscle cells,” The Journal of Biological
Chemistry, vol. 277, no. 12, pp. 9676–9683, 2002.
[47] S. Yavrom, L. Chen, S. Xiong, J. Wang, R. A. Rippe, and
H. Tsukamoto, “Peroxisome proliferator-activated receptor γ
suppresses proximal α1(I) collagen promoter via inhibition
of p300-facilitated NF-I binding to DNA in hepatic stellate
cells,” The Journal of Biological Chemistry, vol. 280, no. 49, pp.
40650–40659, 2005.
[48] S. Ohga, K. Shikata, K. Yozai, et al., “Thiazolidinedione
ameliorates renal injury in experimental diabetic rats through
anti-inﬂammatory eﬀects mediated by inhibition of NF-κB
activation,” American Journal of Physiology, vol. 292, no. 4, pp.
F1141–F1150, 2007.